News Sentiment

URGN sentiment intelligence

UroGen Pharma Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 40.23 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+4.3% over one week, +19.8% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

URGN stock trades steady as UroGen revenue grows and pipeline advances

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 4.3% Price confirming higher
Trend fit Trend active 19.8% over four weeks
Fair value 140.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 35
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 10
Investing.com 5
simplywall.st 5
MT Newswires 4
TradingView 3
Sahm 3
Quartr 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 13
Analyst action 8
Regulatory and legal 6
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Simply Wall Street Direct company coverage

What UroGen Pharma (URGN)'s UGN-501 IND Clearance Means For Shareholders

UroGen Pharma received IND clearance for UGN-501, an oncolytic virus for non-muscle invasive bladder cancer, allowing a Phase 1 trial to commence. While this expands their pipeline, the company's near-term focus remains on the uptake of ZUSDURI and the regulatory path for UGN-103

Tone
Neutral 50/100
Event
Regulatory and legal
Published
21 Jul 2026 05:12
Source
Simply Wall Street
TradingView Direct company coverage

Price to sales forward of UroGen Pharma Ltd. – MUN:UR8

This article focuses on the "Price to sales forward" financial metric for UroGen Pharma Ltd. (MUN:UR8) available on TradingView. It appears to be a financial data snippet or a specific data point rather than a detailed analytical article. The content is primarily a listing of fin

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 02:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of UroGen Pharma Ltd. – NASDAQ:URGN

This article provides a brief financial update for UroGen Pharma Ltd. (NASDAQ: URGN), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed with no trades recorded at the time of the report. The content appears to be a stub or a placeh

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 00:12
Source
TradingView
Quartr Direct company coverage

UroGen Pharma (URGN) AGM 2026 Summary

UroGen Pharma's 2026 AGM highlighted the successful launch of ZUSDURI, a new FDA-approved bladder cancer treatment, and continued growth of JELMYTO. The meeting also addressed the advancement of pipeline products like UGN-103, UGN-104, and UGN-501, and nominated seven directors f

Tone
Positive 72/100
Event
Market update
Published
20 Jul 2026 02:09
Source
Quartr
Sahm Direct company coverage

UroGen Pharma (URGN) Rallies On FDA Clearance As Valuation Questions Grow

UroGen Pharma (URGN) has rallied significantly following FDA clearance for its UGN-501, allowing a Phase 1 bladder cancer study. While the stock has seen impressive returns, current analyst narratives suggest it is overvalued at $36.11, despite a Simply Wall St DCF model indicati

Tone
Neutral 50/100
Event
Analyst action
Published
19 Jul 2026 02:09
Source
Sahm
Investing.com Direct company coverage

Urogen Pharma stock hits 52-week high at 41.45 USD

Urogen Pharma's stock has reached a 52-week high of $41.45, reflecting strong investor confidence and significant year-to-date gains. The company has several positive developments, including an increased price target from Oppenheimer, a new patent for bladder cancer treatment, an

Tone
Positive 93/100
Event
Analyst action
Published
18 Jul 2026 13:41
Source
Investing.com
Barchart.com Direct company coverage

Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027

UroGen Pharma (URGN) has experienced significant stock growth and strong technical indicators, with analysts predicting substantial revenue and earnings increases in the coming years. Despite this positive outlook and five years of revenue growth, the company remains unprofitable

Tone
Positive 76/100
Event
Earnings
Published
18 Jul 2026 09:15
Source
Barchart.com
Investing.com South Africa Direct company coverage

Urogen Pharma stock hits 52-week high at 41.45 USD By Investing.com

Urogen Pharma Ltd.'s stock reached a 52-week high of $41.45, now trading just under 1% below its peak with significant year-to-date and six-month returns. This surge follows positive developments including Oppenheimer raising its price target to $50, a patent allowance for bladde

Tone
Positive 94/100
Event
Analyst action
Published
18 Jul 2026 00:09
Source
Investing.com South Africa
Investing.com Direct company coverage

Oppenheimer raises UroGen Pharma stock price target to $50 on sales outlook

Oppenheimer has increased its price target for UroGen Pharma (NASDAQ:URGN) to $50 from $40, maintaining an Outperform rating, based on increased sales projections for their Jelmyto product. The firm's updated estimates for Jelmyto sales in 2026-28 are $210 million, $448 million,

Tone
Positive 85/100
Event
Analyst action
Published
16 Jul 2026 11:58
Source
Investing.com
Investing.com Australia Direct company coverage

H.C. Wainwright reiterates UroGen Pharma stock rating on patent news By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $45.00 price target for UroGen Pharma (NASDAQ:URGN) after the company received a Notice of Allowance for a patent related to treating low-grade intermediate-risk non-muscle-invasive bladder cancer. This patent, supported by data f

Tone
Neutral 50/100
Event
Analyst action
Published
16 Jul 2026 11:39
Source
Investing.com Australia
Moomoo Direct company coverage

Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44

Goldman Sachs has reiterated its Hold rating on UroGen Pharma Ltd (URGN.US) and has increased its price target for the company's stock to $44. This adjustment reflects a continued neutral stance on the company's prospects while revising the expected valuation upwards.

Tone
Positive 70/100
Event
Analyst action
Published
16 Jul 2026 01:10
Source
Moomoo
Quartr Direct company coverage

UroGen Pharma (URGN) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

UroGen Pharma (URGN) presented at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026, highlighting its RTGel technology for sustained drug delivery in urothelial cancer. The company discussed the commercial success of its products, JELMYTO and ZUSDURI, with ZUSDURI's

Tone
Positive 76/100
Event
Guidance
Published
15 Jul 2026 13:41
Source
Quartr
GlobeNewswire Direct company coverage

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

UroGen Pharma Ltd. announced it received a U.S. patent allowance extending protection for ZUSDURI™ and investigational UGN-103 into July 2044. The patent covers methods for treating recurrent, low-grade intermediate-risk non-muscle-invasive bladder cancer without transurethral re

Tone
Positive 74/100
Event
Regulatory and legal
Published
15 Jul 2026 12:15
Source
GlobeNewswire
BioBuzz Direct company coverage

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd. announced that the FDA has cleared its Investigational New Drug (IND) application for UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). This clearance allows the company to initiate a Phase 1 clinical study in Q4 2026 to

Tone
Positive 72/100
Event
Regulatory and legal
Published
15 Jul 2026 00:15
Source
BioBuzz
Market source Direct company coverage

UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 10,000 shares worth $400,000 as the final transaction of a pre-established 10b5-1 trading plan. Despite the sale, Schoenberg retains a significant stake of nearly $4.8 million in the company. The article notes this tran

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 Jul 2026 11:41
Source
Market source
Sahm Direct company coverage

UroGen Pharma (URGN) Is Up 5.8% After FDA Clears IND For UGN-501 Phase 1 Trial

UroGen Pharma's stock rose 5.8% after the FDA cleared its Investigational New Drug application for UGN-501, an oncolytic virus intended for a Phase 1 trial in non-muscle invasive bladder cancer. This clearance expands UroGen's pipeline beyond bladder cancer and diversifies its in

Tone
Positive 71/100
Event
Regulatory and legal
Published
11 Jul 2026 14:09
Source
Sahm
Investing.com Direct company coverage

UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares

Mark Schoenberg, Chief Medical Officer of UroGen Pharma (NASDAQ:URGN), sold 10,000 ordinary shares for $400,000 on July 9, 2026, at an average price of $40.00 per share. This sale, executed under a pre-arranged trading plan, occurred as the stock traded near its 52-week high afte

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 18:10
Source
Investing.com
Investing.com Canada Direct company coverage

Form 4 Urogen Pharma Ltd For: 10 July By Investing.com

This Investing.com article is a brief financial notice indicating a Form 4 filing for Urogen Pharma Ltd on July 10. Such filings typically report changes in ownership of company securities by insiders. The article includes the stock symbol URGN and notes a -4.15% change.

Tone
Negative 40/100
Event
Market update
Published
10 Jul 2026 18:10
Source
Investing.com Canada
Stock Titan Direct company coverage

UroGen Pharma (URGN) CMO Mark Schoenberg sells 10,000 shares via Rule 10b5-1 plan

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 10,000 Ordinary Shares of URGN at a weighted average price of $40.00 per share. This transaction was conducted under a pre-established Rule 10b5-1(c) trading plan adopted on August 15, 2025, and represents the final sal

Tone
Negative 36/100
Event
Market update
Published
10 Jul 2026 18:10
Source
Stock Titan